Grant

Actuate 1801. Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3B) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies

Active

$432.5K Funding

7 People

External

Hina Arif Tiwari
Co-Investigator (COI)
Pathology and Lab Medicine﹒Professor
Rachna Shroff
Principal Investigator (PI)
Medicine﹒Professor
Brianna Denton
(CD)
Cancer Center Division﹒Research Compliance Manager I
Brianna Loughran
(CD)
Cancer Center Division﹒Clinical Research Coordinator II
Diana Dawson
(CD)
Cancer Center Division﹒Research Compliance Administrator II
Bryan Clines
(CD)
Cancer Center Division﹒Research Compliance Administrator III
Aaron Scott
Co-Investigator (COI)
Medicine﹒Associate Professor, Medicine - (Clinical Scholar Track)